The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis.

ABSTRACT:

Background and purpose

Apatinib is a novel, oral, small-molecule tyrosine kinase inhibitor that targets VEGFR-2. Recent clinical trials have revealed its broad-spectrum anticancer effect. However, most recent studies of apatinib have involved single-arm studies with insufficient cases, different doses of drugs, and different incidences of adverse events (AEs), which has resulted in a lack of accurate measurement of the efficacy and safety of apatinib. Thus, we performed this meta-analysis to evaluate the efficacy and safety of apatinib.

Methods

In total, 21 studies from five databases (PubMed, ScienceDirect, ClinicalTrials.gov, China National Knowledge Infrastructure [CNKI], and Cochrane Library) were included in this meta-analysis. All statistical analyses in this meta-anal

SUBMITTER: Sun D 

PROVIDER: S-EPMC6178936 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature